Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-?B expressions

Basit Öğe Kaydı
dc.contributor.authorOltulu, Fatih
dc.contributor.authorBuhur, Aylin
dc.contributor.authorGürel, Çevik
dc.contributor.authorKuşçu, Gökçe Ceren
dc.contributor.authorDağdeviren, Melih
dc.contributor.authorYavaşoğlu, Nefise Ülkü Karabay
dc.contributor.authorYavaşoğlu, Altuğ
dc.date.accessioned2021-05-03T21:13:53Z
dc.date.available2021-05-03T21:13:53Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage in a streptozotocin (STZ, 50 mg/kg)-induced DM model in rats. Materials and methods: In this study, five different groups were formed: control, DM, low-dose losartan (5 mg/kg), mid-dose losartan (20 mg/kg), and high-dose losartan (80 mg/kg). Liver tissues of experimental groups were evaluated immunohistochemically for TUNEL, iNOS, eNOS, VEGF, and NF-?B pathways. In addition to immunohistochemical analysis, analyses of SOD and MDA, which are oxidative stress markers, were also performed and the results were evaluated together. Results: When biochemical and immunohistochemical findings were evaluated together, it was found that the results obtained from the mid-dose losartan group were closer to those of the control than the other groups. Conclusion: This study indicated that mid-dose losartan administration may have a therapeutic effect by inhibiting apoptosis and regulating iNOS, eNOS, VEGF, and NF-?B protein expressions in DM-induced hepatic damage.en_US
dc.identifier.doi10.3906/sag-1901-15
dc.identifier.endpage1589en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1582en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1901-15
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpNMk9UWXlNZz09
dc.identifier.urihttps://hdl.handle.net/11454/71680
dc.identifier.volume49en_US
dc.identifier.wosWOS:000504050500048en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titleMid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-?B expressionsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu